Estimated read time: Less than a minute
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
LONDON (AFX) - Merck & Co Inc said its cervical cancer vaccine Gardasil received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Europe.
The CHMP opinion recommends that Gardasil be approved for the immunization of children and adolescents aged 9 to 15 years and of adult females aged 16 to 26 years for the prevention of cervical cancer, high-grade cervical dysplasia, high-grade vulvar dysplastic lesions and external genital warts caused by human papilloma virus.
Following the CHMP review, the opinion for Gardasil is transmitted to the European Commission.
Gardasil will be marketed by Sanofi Pasteur MSD (SPMSD), a joint venture between Sanofi Pasteur and Merck, in the EU. newsdesk@afxnews.com jc COPYRIGHT Copyright AFX News Limited 2005. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
Copyright 2006 AFX News Limited. All Rights Reserved.
